Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist With Multimodal Activity, in Major Depressive Disorder: Results From the GEMINI Trial

被引：0
|
作者：
Jones, Amanda [3 ]
O'Gorman, Cedric [3 ]
Streicher, Caroline [3 ]
Feliz, Samantha [3 ]
Iosifescu, Dan V. [1 ,2 ]
Tabuteau, Herriot [3 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Nathan S Kline Inst Psychiat Res, Orangeburg, NY USA
[3] Axsome Therapeut, New York, NY USA
来源：
ANNALS OF CLINICAL PSYCHIATRY | 2021年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
11
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of AXS-05, an oral, NMDA receptor antagonist with multimodal activity in major depressive disorder
    O'gorman, C.
    Jones, A.
    Iosifescu, D.
    Tabuteau, H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S190 - S190
  • [2] Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the ASCEND Phase 2, Double-Blind, Active-Controlled Trial
    Jones, Amanda
    O'Gorman, Cedric
    Jacobson, Mark
    Iosifescu, Dan V.
    Tabuteau, Herriot
    [J]. NEUROTHERAPEUTICS, 2021, 18 (03) : 2138 - 2139
  • [3] EFFECTS OF AXS-05 ON PATIENT REPORTED DEPRESSIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE GEMINI TRIAL
    O'Gorman, C.
    Feliz, S.
    Jones, A.
    Streicher, C.
    Thomas, Z.
    Tabuteau, H.
    [J]. VALUE IN HEALTH, 2021, 24 : S135 - S135
  • [4] Impact of AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder
    Jones, Amanda
    McIntyre, Roger S.
    Jacobsen, Mark
    Streicher, Caroline
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. CNS SPECTRUMS, 2023, 28 (02) : 264 - 264
  • [5] Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials
    O'Gorman, Cedric
    Jones, Amanda
    Iosifescu, Dan V.
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S244 - S244
  • [6] Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)
    Iosifescu, Dan V.
    Jones, Amanda
    O'Gorman, Cedric
    Streicher, Caroline
    Feliz, Samantha
    Fava, Maurizio
    Tabuteau, Herriot
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (04)
  • [7] EARLY IMPROVEMENTS IN FUNCTIONING AND QUALITY OF LIFE WITH AXS-05 IN MAJOR DEPRESSIVE DISORDER: RESULTSFROM THE GEMINI TRIAL
    Jones, A.
    Feliz, S.
    O'Gorman, C.
    Streicher, C.
    Thomas, Z.
    Tabuteau, H.
    [J]. VALUE IN HEALTH, 2021, 24 : S135 - S135
  • [8] Rapid Antidepressant Effects and MADRS Core Symptom Improvements With AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials
    O'Gorman, Cedric
    Jones, Amanda
    Anderson, Ashley
    Jacobson, Mark
    Feliz, Samantha
    Streicher, Caroline
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 201 - 202
  • [9] Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder
    Gaca, Zuzanna
    Pruc, Michal
    Swieczkowski, Damian
    Kwasny, Aleksander
    Szarpak, Lukasz
    Cubala, Wies law J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2024, 86 : 18 - 19
  • [10] Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials
    Jones, Amanda
    Streicher, Caroline
    Alter, Shawn
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. CNS SPECTRUMS, 2023, 28 (02) : 263 - 263
12345